When supplies resume, should governments subsidise drugs like Ozempic for weight loss? We asked 5 experts

What are Ozempic and Wegovy, and why are they in short supply?

Hundreds of thousands of people worldwide are taking drugs like Ozempic to lose weight. But what do we actually know about them? This month, The Conversation’s experts explore their rise, impact and potential consequences. You’ve no doubt heard of Ozempic but have you heard of Wegovy? They’re both brand names of the drug semaglutide, which is currently in short supply worldwide.

Ozempic is a lower dose of semaglutide, and is approved and used to treat diabetes in Australia. Wegovy is approved to treat obesity but is not yet available in Australia. Shortages of both drugs are expected to last throughout 2024.

Both drugs are expensive. But Ozempic is listed on Australia’s Pharmaceutical Benefits Schedule (PBS), so people with diabetes can get a three-week supply for A$31.60 ($7.70 for concession card holders) rather than the full price ($133.80). Wegovy isn’t listed on the PBS to treat obesity, meaning when it becomes available, users will need to pay the full price.

- Advertisement -

Should the government subsidise Wegovy for weight loss?

Wegovy’s manufacturer will need to make the case for it to be added to the PBS to an independent advisory committee. The company will need to show Wegovy is a safe, clinically effective and cost-effective treatment for obesity compared to existing alternatives.

Expert opinions on subsidising Wegovy for weight loss

We asked five experts: when supplies resume, should governments subsidise drugs like Ozempic for weight loss?

Four out of five said yes

Here are their detailed responses:

In this article, we will present the responses from five experts, along with an infographic that illustrates their answers. Then, we will discuss the potential consequences and limitations of subsidising drugs like Ozempic for weight loss.

Potential consequences and limitations of subsidising Wegovy for weight loss

Subsidising Wegovy for weight loss could have several potential consequences and limitations, including:

• The drug may be prescribed more widely, which could lead to increased costs and a higher demand for the drug.
• The drug may not be as effective for weight loss as other treatments, such as surgery or lifestyle changes.
• The drug may have serious side effects, such as pancreatitis or pancreatic cancer, which could be costly to treat.
• The drug may not be suitable for all patients, particularly those with certain medical conditions or allergies.

Conclusion

Subsidising drugs like Ozempic for weight loss is a complex issue that requires careful consideration of the potential benefits and limitations. While some experts believe that governments should subsidise Wegovy for weight loss, others argue that it may not be the most effective or safe treatment for weight loss. Ultimately, the decision to subsidise Wegovy will depend on a thorough assessment of its efficacy, safety, and cost-effectiveness compared to other treatments for weight loss.

FAQs

What are Ozempic and Wegovy?

Ozempic and Wegovy are brand names for the drug semaglutide, which is used to treat diabetes and obesity.

Why are Ozempic and Wegovy in short supply?

Ozempic and Wegovy are currently in short supply due to manufacturing issues and increased demand for the drugs.

Can I get Ozempic and Wegovy in Australia?

Ozempic is approved and used to treat diabetes in Australia, while Wegovy is not yet available in Australia due to the shortage.

How much does Ozempic and Wegovy cost?

Ozempic costs A$31.60 for a three-week supply, while Wegovy will require users to pay the full price once it becomes available.

Will Wegovy be subsidized by the government?

Wegovy’s manufacturer will need to make the case for it to be added to the PBS to an independent advisory committee, which will assess its safety, efficacy, and cost-effectiveness compared to other treatments for weight loss.

Should governments subsidise drugs like Ozempic for weight loss?

The answer depends on the assessment of its safety, efficacy, and cost-effectiveness compared to other treatments for weight loss. Four out of five experts said yes, while one expert disagreed.